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ABSTRACT 
Objective: Assess the validity of seven type 2 diabetes mellitus (T2DM) risk scores in predicting the 10-year 
incidence of T2DM in a Swiss population based study. 
Methods: prospective study including 5131 participants (55% women, age range 35 to 75 years) living in 
Lausanne, Switzerland. The baseline survey was conducted between 2003 and 2006 and average follow-up was 
10.9 years. Five clinically-based (Balkau, Kahn clinical, Griffin, Swiss diabetes association and Findric) and two 
clinically and biologically based scores (Kahn CB and Wilson) were tested. 
Results: 405 (7.9%) participants developed T2DM. The overall prevalence of participants at high risk ranged 
from 13.7% for the Griffin score to 43.3% for the Balkau score. Prevalence of participants at high risk among 
those who developed T2DM ranged from 34.6% for the Griffin score to 82.0% for the Kahn CB score. The Kahn 
CB score had the highest area under the ROC [value and 95% confidence interval: 0.866 (0.849-0.883)], 
followed by the Findrisc [0.818 (0.798-0.838)] while the Griffin score had the lowest [0.740 (0.718-0.762)]. 
Except for the Griffin and the Kahn C scores (for sensitivity) and the Balkau score (for specificity), sensitivities 
and specificities were above 70%. The numbers needed to screen ranged between 15.5 for the Kahn CB score 
to 36.7 for the Griffin score. 
Conclusion: The Kahn (CB) and the Findrisc performed best of all scores. Findrisc could be used in the 
epidemiological setting, while the need of blood sampling for the Kahn (CB) score restricts its use to a more 
clinical setting. 
Keywords: type 2 diabetes mellitus; risk scores; prospective study; epidemiology 
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INTRODUCTION: 
The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide (1). In Switzerland, one out 
of sixteen persons aged between 35 and 75 years has diabetes mellitus, and almost one third of diabetic 
subjects is unaware of their status (2) T2DM carries a considerable economic burden (3) as patients with T2DM 
are at higher risk of developing cardiovascular, neurological, renal and ophthalmic complications. Hence, early 
diagnosis of T2DM is of major importance as the outcome of the disease can be modified through medical care 
and lifestyle changes (4). The identification of subjects at high risk of developing T2DM might also be cost-
effective by reducing the incidence of T2DM (5). Therefore, multiple predictive risk scores have been 
developed to detect patients at high risk of developing T2DM (6). Such scores rely mainly on anamnestic and 
clinical information such as personal or family history and on simple measurements such as blood pressure, 
weight or waist. Some scores use additional blood markers such as fasting glucose, cholesterol and 
triglycerides. While scores including blood markers tend to perform better, their cost is higher (6). Further, 
most scores have been validated in selected populations, and their application in other settings or populations 
is not warranted.  
In a previous study, we assessed the 5.5-year predictive capacity of seven T2DM risk scores in a 
prospective, population-based sample (7). As many scores were originally developed using longer follow-up 
times, a further validation was deemed necessary. Hence, in this study, we aimed to validate the seven above-
mentioned T2DM risk scores over a 10-year follow-up. Our initial hypothesis was that the predictive capacity 
of each score would not change significantly in a longer follow-up. 
METHODS 
The Colaus study 
The sampling procedure of the CoLaus cohort has been described previously (8) and further details 
can be obtained in www.colaus-psycolaus.ch. Briefly, the source population was defined as all subjects aged 
between 35 and 75 years registered in the population register of the city of Lausanne. The register includes all 
subjects living in this city for more than 90 days. A simple, non-stratified random sample of 19’830 subjects 
(corresponding to 35% of the source population) was drawn and the selected subjects were invited to 
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participate by letter. If no answer was obtained, a second letter was sent, and if no answer was obtained, the 
subjects were contacted by phone. Recruitment began in June 2003 and ended in May 2006, enrolling 6733 
total participants who underwent an interview, a physical exam, and a blood analysis. The first follow-up was 
performed between April 2009 and September 2012, 5.6 years on average (media 5.4 years, range 4.5-8.8) 
after the collection of baseline data; the second follow-up was performed between May 2014 and April 2017, 
10.9 years on average (median 10.7, range 8.8-13.6) after the collection of baseline data. The information 
collected was similar to that collected in the baseline examination. 
Data collection 
Participants were asked to attend an outpatient clinic at Centre Hospitalier Universitaire Vaudois in 
the morning, after an overnight fast. Socio-demographic, history of disease (personal and familiar) and lifestyle 
data was collected by questionnaire. Smoking was categorized as never, former and current; alcohol 
consumption was assessed by the number of alcoholic drinks (i.e. glasses of wine, cans of beer or shots of 
spirit) consumed the last seven days and categorized into none, moderate (1-13 units/week), high (14-27 
units/week) and very high (28+ units/week). Educational level was categorized as low (primary), middle 
(apprenticeship), upper middle (high school), and high (university) for highest completed level of education. 
Physical activity was defined by exercising at least twice per week for at least 20 minutes per session. 
Prescribed and over-the-counter medicines were collected by questionnaire. 
Body weight and height were measured with participants barefoot and in light indoor clothes. Body 
weight was measured in kilograms to the nearest 100 g using a Seca® scale (Hamburg, Germany). Height was 
measured to the nearest 5 mm using a Seca® (Hamburg, Germany) height gauge. Waist circumference was 
measured mid-way between the lowest rib and the iliac crest using a non-stretchable tape and the average of 
two measurements was taken. Blood pressure (BP) and resting heart rate were measured thrice using an 
Omron® HEM-907 automated oscillometric sphygmomanometer after at least a 10-minute rest in a seated 
position. Different sized cuffs were available to take into account arm cirumference and the average of the last 
two measurements was used.  
Venous blood samples (50 mL) were drawn in the fasting state. Biological assays were performed at 
the clinical laboratory of the Lausanne university hospital within 2 hours of blood collection. Glucose was 
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assessed by glucose dehydrogenase with a maximum inter- and intra-assay CV of 2.1% and 1.0%, respectively; 
HDL-cholesterol by CHOD-PAP + PEG + cyclodextrin (3.6%-0.9%); triglycerides by GPO-PAP (2.9%-1.5%), and 
uric acid by uricase-PAP (1.0%-0.5%). Glycated hemoglobin was measured by high performance liquid 
chromatography (HPCL) using Bio-Rad, D-10TM system, with measurement range 3.8% (at 18 mmol/mol) to 
18.5% (at 179 mmol/mol). 
Diabetes risk scores 
Seven DM risk scores were considered: 1) the FINDRISC (9) ; 2) the Swiss Diabetes Association (SDAS) 
(10) ; 3) the clinical and clinico-biological scores by Kahn et al., respectively (11); 4) the clinico-biological risk 
score by Wilson et al. (12); 5) the clinical risk score by Balkau et al. (13), and 6) the clinical risk score by Griffin 
et al. (14). The details of each score are summarized in supplemental table 1. 
The FINDRISC score was derived from the 10 year follow-up FINRISK study consisting of 4435 
participants (9) and consists of seven variables. The Swiss Diabetes Association risk score (SDAS) is adapted 
from the FINDRISC, using familial history of diabetes as an additional variable. The risk scores by Kahn et al (11) 
were derived in a cohort of 15’792 adults followed up during 10 years. The clinical risk score (C) consists of 
nine variables, while the clinic-biological risk score (CB) has four additional biological markers. The clinic-
biological risk score of Wilson et al. (12) was derived from the Framingham Offspring Study, where 3140 
participants were followed up 8 years; the score consists of six variables (three clinical and three biological). 
The clinical risk score of Balkau et al (13) was derived from the DESIR cohort, where 3817 participants were 
followed for nine years; it consists of four variables. Finally, the score of Griffin et al (14) was derived from a 
cross-sectional study consisting of 1077 participants, and is composed of five clinical variables. 
The FINDRISC, SDAS, Kahn (C and B), Wilson and Balkau scores are based on a sum of allocated 
number of points per variable. For the FINDRISC and SDAS, nutritional variables and familial history of diabetes 
for second-degree parents were not available at baseline; thus, the threshold was reduced by 1 point. The 
Griffin score uses a regression equation to calculate the probability of developing T2DM. As no threshold had 
been proposed in the original study, a 37% probability was used to identify high-risk individuals, as proposed 
elsewhere (11). 
Outcome 
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The primary outcome was T2DM, defined as fasting blood glucose ≥7.0 mmol/l or taking insulin or oral 
antidiabetic medication. 
Exclusion criteria 
The original inclusion criteria were: 1) written informed consent; 2) willingness to take part in the 
examination and to provide blood samples; 3) French language ability. For this study, we added the following 
exclusion criteria: 1) diabetes (type 1 or 2) at baseline; 2) no follow-up (first or second); 3) missing variables to 
compute the scores and 4) no outcome data. 
Ethical statement 
The institutional Ethics Committee of the University of Lausanne, which afterwards became the Ethics 
Commission of Canton Vaud (www.cer-vd.ch) approved the baseline CoLaus study (reference 16/03, decisions 
of 13th January and 10th February 2003); the approval was renewed for the first (reference 33/09, decision of 
23rd February 2009) and the second (reference 26/14, decision of 11th March 2014) follow-up. The study was 
performed in agreement with the Helsinki declaration and its former amendments, and in accordance with the 
applicable Swiss legislation. All participants gave their signed informed consent before entering the study. 
Statistical analysis 
Statistical analyses were conducted using Stata version 15.1 for Windows (Stata Corp, College Station, 
Texas, USA). Participants characteristics were expressed as number (percentage) for categorical variables or as 
average±standard deviation for continuous variables. Between-group comparisons were performed using chi-
square or Fisher’s exact test for categorical variables and student’s t-test or Kruskal-Wallis test for continuous 
variables.  
Risk scores were expressed as median and [interquartile range]. The diagnostic capacity of the 
different risk scores was assessed by the AUC [area under the ROC (receiver operating characteristic) curve] 
and corresponding 95% confidence intervals (CI). Comparisons of the AUC between scores were performed 
using the roccomp command of Stata. Sensitivity, specificity, positive and negative predictive values and their 
corresponding 95% CIs were computed using incident T2DM as gold standard. The number needed to screen 
(NNS) to detect one case of T2DM was computed as the total number of participants screened divided by the 
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number of detected T2DM cases (i.e. true positives). Statistical significance was assessed for a two-sided test 
with p<0.05. 
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RESULTS 
Characteristics of participants 
Of the initial 6733 participants 5131 (76.2%) were retained for analysis. The reasons for exclusion are 
summarized in figure 1 and the characteristics of the included and the excluded participants are summarized 
in the supplementary table 2. Included participants were younger; had lower waist and BMI; had lower 
prevalence of hypertension and family history of diabetes; had lower levels of fasting plasma glucose and uric 
acid than excluded ones. Included participants also had higher caffeine and alcohol consumption and higher 
levels of physical activity and HDL than excluded ones. 
Incidence of T2DM 
At the second follow-up, 405 (7.9%) participants developed T2DM. The baseline characteristics of the 
participants who developed and did not develop T2DM are summarized in table 2. Participants who developed 
T2DM were more frequently male, were older, had higher waist and BMI, a higher prevalence of family history 
of diabetes and hypertension or of being former or current smokers, had a higher alcohol consumption and 
higher levels of fasting plasma glucose, triglycerides, HDL and uric acid. 
Performance of risk scores 
The median score and the prevalence of participants at high risk of developing T2DM overall and 
according to (non)development of T2DM are provided in table 2 for each risk score. The overall prevalence of 
participants at high risk ranged from 13.7% for the Griffin score to 43.3% for the Balkau score. Prevalence of 
participants at high risk among those who developed T2DM ranged from 34.6% for the Griffin score to 82.0% 
for the Kahn CB score (table 2). 
The AUC, sensitivity, specificity, positive and negative predictive values and the number needed to 
screen to detect one case of T2DM are summarized in table 3 for each risk score. The AUCs for each score are 
also provided in Figure 2 and the results of the bivariate comparisons of the AUCs are provided in table 4. The 
Kahn CB score had the highest AUC while the Griffin score had the lowest. Except for the Griffin and the Kahn C 
scores (for sensitivity) and the Balkau score (for specificity), sensitivities and specificities were above 70%. 
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Positive predictive values were below 25%, while negative predictive values were above 90%. The numbers 
needed to screen ranged between 15.5 for the Kahn CB score to 36.7 for the Griffin score (table 3). 
DISCUSSION 
Out of the seven diabetes risk scores evaluated, the two with the highest AUC were the Kahn et al 
(CB), which includes biological variables, and the Findrisc, which is based on clinical data only. This finding is 
comparable to what was reported previously using a shorter follow-up period (5.5 vs. 10.9 years) (7). 
Importantly, our results confirm our hypothesis that the predictive value of a diabetes risk score does not 
change significantly when follow-up times shorter than the ones used for the original validation are used. 
Diabetes risk scores  
The Kahn (CB) score showed the best metrics, a finding already reported previously (7). Several 
reasons might explain this performance: first, it was developed using a large sample size (12’729) and included 
four blood markers. Although the inclusion of blood markers might improve the predictive capacity of the 
score, it also makes it more expensive to use either for mass screening or for everyday clinical use. Hence, it 
applicability in settings with limited health resources will be reduced. The Wilson score also includes biological 
markers but, contrary to the Kahn CB, its predictive capacity was rather low and its AUC was comparable to the 
clinical version of the Kahn score. 
The Findrisc score ranked second highest among all scores. Contrary to the Kahn (CB) score, the 
Findrisc score is based solely on clinical data and can thus be applied in screening campaigns or in communities 
with limited health resources. Importantly, although the complete version of the Findrisc score could not be 
used in this study, still the reduced version performed well, suggesting that the performance of the complete 
version, if computable, could even be better. Further, the SDAS, which is based on the Findrisc, also showed an 
adequate performance, albeit with a lower AUC than the Findrisc. The likely reason is an arbitrary addition of 5 
points for family history of diabetes on the SDAS, which does not seem to improve its performance. The Balkau 
score had the lowest number of components. Although this small number of items might facilitate its 
applicability in public health or in clinical practice, its predictive capacity was modest, and it led to a very high 
number of participants classified as being “at risk”. Finally, the Griffin score had the lowest prediction capacity. 
A probable explanation is that it was developed in a cross-sectional setting, whereas the other scores were 
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developed in a prospective setting. Overall, our results indicate that a prospective setting is paramount to 
adequately derive and validate a risk prediction score. Indeed, most scores perform well in the populations 
they were developed in, but their predictive value drops when applied to a different cohort. Hence, externally 
validating predictive scores on different populations is essential to assess their generalizability and 
performance. 
Strengths and limitations 
The main strength of our study is that we used a follow-up time similar to the one the scores were 
developed for. The second strength is the relatively large sample size, which provided an adequate number of 
incident events. 
We also acknowledge several limitations. Firstly, no nutritional data was collected at baseline; hence, 
we had to adapt the threshold of the Findrisc and SDAS scores by reducing the threshold by one unit, a 
procedure also performed in our previous study (7). Still, despite this limitation, both the Findrisc and the SDAS 
scores performed better than other scores. Secondly, the CoLaus study includes a majority of Caucasian 
subjects lving in a high-income country and in an urban setting; hence, generalizability to other ethnicities or 
other settings might not be warranted. It would be important that our study be replicated in other cohorts to 
validate the robustness of our findings. Thirdly, we lost approximately 15% of our baseline cohort during the 
first and the second follow-up, which might have reduced the number of incident T2DM events. Still, this 
impacted equally all scores and would not change the conclusions of the study. 
Conclusion 
The Kahn (CB) and the Findrisc performed best of all scores. Findrisc could be used in the 
epidemiological setting, while the need of blood sampling for the Kahn (CB) score restricts its use to a more 
clinical setting.
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Figure legends 
Figure 1: exclusion criteria. Results are expressed as number of participants and (percentage) using the 
baseline number of subjects as denominator. 
Baseline survey
N=6733
Final sample
N=5131 (76.2%)
No 1st or 2nd follow-up
N=1005 (14.9%)
Diabetes 1 or 2 at baseline
N= 436 (6.5%)
No outcomes
N=146 (2.2%)
No covariates
N=15 (0.2%)
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Figure 2: ROC curves of  the seven diabetes risk scores. 
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Tables 
Table 1: Factors associated with incident diabetes, 10.9-year follow-up, CoLaus study, Lausanne, Switzerland 
 No diabetes Incident diabetes P-value 
N 4726 405  
Gender (women) 2669 (56.5) 149 (36.8) <0.001 
Age (years) 51.3 ± 10.5 55.9 ± 9.8 <0.001 
Clinical data    
Weight (kg) 71.3 ± 13.9 82.5 ± 14.2 <0.001 
Body mass index (kg/m2) 25.1 ± 4.0 28.7 ± 4.3 <0.001 
Waist (cm) 86.7 ± 12.1 98.7 ± 11.5 <0.001 
Hypertension (%) 2073 (43.9) 294 (72.6) <0.001 
Resting heart rate (bpm) 67 ± 9 69 ± 10 0.008 
Family history of diabetes (%) 980 (20.7) 137 (33.8) <0.001 
High glucose (≥ 6.1 mmol/L) 1339 (28.4) 318 (78.7) <0.001 
Prescribed steroids (%) 20 (0.4) 3 (0.7)  
Lifestyle data    
Alcohol consumption (%)   <0.001 
None 1254 (26.5) 107 (26.4)  
1-13 UA/week 2733 (57.8) 212 (52.4)  
14-27 UA/week 601 (12.7) 58 (14.3)  
≥28 UA/week 138 (2.9) 28 (6.9)  
Smoking categories (%)   0.001 
Never 1987 (42.0) 132 (32.6)  
Former 1519 (32.1) 151 (37.3)  
Current 1220 (25.8) 122 (30.1)  
Caffeinated drinks consumption (%)   0.135 
None 289 (6.1) 25 (6.2)  
1-3 u/day 3075 (65.1) 264 (65.2)  
4-6 u/day 1158 (24.5) 89 (22.0)  
>6 u/day 204 (4.3) 27 (6.7)  
Physical activity (%) 2687 (56.9) 181 (44.7) <0.001 
Blood markers    
Fasting plasma glucose (mmol/l) 5.3 ± 0.5 6.0 ± 0.6 <0.001 
Triglycerides (mmol/l) 1.27 ± 0.96 1.99 ± 1.99 <0.001 
HDL (mmol/l) 1.68 ± 0.44 1.46 ± 0.37 <0.001 
Uric acid (µmol/l) 303 ± 81 353 ± 87 <0.001 
UA, units of alcohol. Results expressed as average ± standard deviation or as number of participants and 
(percentage). Between-group comparisons performed using student’s t-test or Kruskal-Wallis test (§) for 
continuous variables and chi-square or Fisher’s exact test (†) for categorical variables. 
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Table 2: Bivariate analysis of diabetic risk scores, 10 year follow-up (2003-2006 to 2014-2017) CoLaus study, 
Lausanne, Switzerland 
 All No diabetes Incident diabetes 
N 5131 4726 405 
Griffin et al.    
Score  11 [3 - 35] 10 [3 - 32] 38 [17 - 66] 
High risk (%) 702 (13.7) 562 (11.9) 140 (34.6) 
Balkau et al.    
Score 2 [1 - 3] 2 [1 - 3] 3 [3 - 4] 
High risk (%) 2222 (43.3) 1905 (40.3) 317 (78.3) 
Kahn et al (C)    
Median scorve 25 [12 - 40] 23 [12 - 38] 44 [32 - 57] 
High risk (%) 1443 (28.1) 1184 (25.1) 259 (64.0) 
Wilson et al    
Probability 3 [3 - 4] 3 [3 - 4] 7 [4 - 18] 
High risk (%) 1552 (30.3) 1236 (26.2) 316 (78.0) 
Swiss Diabetes association    
Score  7 [4 - 12] 7 [3 - 11] 14 [11 - 17] 
High risk (%) 1586 (30.9) 1282 (27.1) 304 (75.1) 
Findrisc    
Score 6 [3 - 10] 6 [3 - 9] 12 [9 - 14] 
High risk (%) 1388 (27.1) 1096 (23.2) 292 (72.1) 
Kahn et al (CB)    
Score  19 [9 - 33] 18 [9 - 30] 47 [35 - 56] 
High risk (%) 1426 (27.8) 1094 (23.2) 332 (82.0) 
Results expressed as median [interquartile range] or as number of participants and (percentage). Between-
group (diabetes and non-diabetes) comparisons using Kruskal-Wallis test or chi-square test. All differences are 
significant at p<0.001 
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Table 3: Diagnostic performance of the diabetic risk scores, 10 year follow-up (2003-2006 to 2014-2017) CoLaus study, Lausanne, Switzerland 
 AUC Sensitivity § Specificity § Positive predictive 
value § 
Negative predictive 
value § 
Number needed to 
screen §§ 
Griffin et al. 0.740 (0.718 - 0.762) 34.6 (29.9 - 39.4) 88.1 (87.2 - 89.0) 19.9 (17.0 - 23.1) 94.0 (93.3 - 94.7) 36.7 
Balkau et al. 0.750 (0.728 - 0.771) 78.3 (73.9 - 82.2) 59.7 (58.3 - 61.1) 14.3 (12.8 - 15.8) 97.0 (96.3 - 97.6) 16.2 
Kahn et al (C) 0.777 (0.755 - 0.798) 64.0 (59.1 - 68.6) 74.9 (73.7 - 76.2) 17.9 (16.0 - 20.0) 96.0 (95.4 - 96.6) 19.8 
Wilson et al. 0.788 (0.765 - 0.811) 78.0 (73.7 - 82.0) 73.8 (72.6 - 75.1) 20.4 (18.4 - 22.5) 97.5 (96.9 - 98.0) 16.2 
Swiss Diabetes association 0.807 (0.787 - 0.828) 75.1 (70.6 - 79.2) 72.9 (71.6 - 74.1) 19.2 (17.3 - 21.2) 97.2 (96.5 - 97.7) 16.9 
Findrisc 0.818 (0.798 - 0.838) 72.1 (67.5 - 76.4) 76.8 (75.6 - 78.0) 21.0 (18.9 - 23.3) 97.0 (96.4 - 97.5) 17.6 
Kahn et al (CB) 0.866 (0.849 - 0.883) 82.0 (77.9 - 85.6) 76.9 (75.6 - 78.0) 23.3 (21.1 - 25.6) 98.0 (97.5 - 98.5) 15.5 
Results expressed as value (95% confidence interval). § Of high vs. low risk; §§ to detect one diabetic case. 
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Table 4: Results of the bivariate comparison of the AUCs between diabetes risk scores. 
    
Model 2 
   
  
Griffin Kahn C Kahn CB Balkau SDAS Findrisc  
Wilson <0.001 0.358 <0.001 0.004 0.047 0.002  
Griffin 
 
<0.001 <0.001 0.319 <0.001 <0.001 
Model 1 Kahn C 
  
<0.001 <0.001 0.001 <0.001  
Kahn CB 
   
<0.001 <0.001 <0.001  
Balkau 
    
<0.001 <0.001  
SDAS 
     
0.029         
  
  Model 1 better   Model 2 better 
Comparisons were performed using the roccomp command of Stata. SDAS, Swiss diabetes association score 
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Supplementary tables 
Supplementary table 1: characteristics of the diabetes risk scores 
 FINDRISC 
Swiss Diabetes 
association 
Wilson et al. Griffin et al. Balkau et al. Kahn et al (C) Kahn et al. (CB) 
Sample size 4’435  3’140 1’077 3’817 12’729 12’279 
Follow-up time 5-10 years  7 years cross-section. 9 years 9 years 9 years 
Incidence of DM 4.1%   5.1% 4.46% 5.61% 19% 19% 
Sex    X X   
Age X X  X  X X 
Clinical data        
BMI X X X X    
Weight      X X 
Waist X X   X X X 
Height      X X 
Hypertension* M M A/M M A/M X X 
Resting heart rate      X X 
Family history of diabetes  X X X X X X 
Personal history of hyperglycemia X X      
Corticosteroids    X    
Lifestyle data        
Physical activity X X      
Smoking    X X X  
Alcohol       X 
Fruit & vegetable consumption X X      
Blood markers        
Glucose   X    X 
Triglycerides   X    X 
High density lipoprotein   X    X 
Uric acid       X 
Score threshold ≥ 9 pts ≥ 9 pts 24 pts  37% ≥5 pts ≥38 pts ≥38 pts 
Risk of developing T2DM 13% 13% 33% 37% 30% 17.7% 17.7% 
BMI, body mass index ; T2DM, type 2 diabetes mellitus. *A: anamnestic, M: antihypertension medication 
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Supplementary table 2: Characteristics of included and excluded participants. 10-year follow-up (2003-2006 to 
2009-2012) CoLaus study, Lausanne, Switzerland 
 Included Excluded P-value 
N 5131 1602  
Gender (Woman %) 2818 (54.9) 726 (45.3) <0.001 
Age (years) 51.7 ± 10.5 55.4 ± 11.1 <0.001 
Clinical data    
Weight (kg) 72.2 ± 14.2 77.0 ± 17.0 <0.001 
Body mass index (kg/m2) 25.4 ± 4.2 27.2 ± 5.3 <0.001 
Waist (cm) 87.6 ± 12.5 93.6 ± 14.7 <0.001 
Hypertension (%) 2367 (46.1) 1011 (63.4) <0.001 
Resting heart rate (bpm) 67 ± 9 70 ± 11 <0.001 
Family history of diabetes (%) 1117 (21.8) 455 (28.4) <0.001 
Prescribed steroids (%) 23 (0.5) 2 (0.1) 0.095† 
Lifestyle data    
Physical activity (%) 2868 (55.9) 727 (45.6) <0.001 
Alcohol consumption (%)   <0.001 
None 1361 (26.5) 554 (34.6)  
1-13 UA/week 2945 (57.4) 708 (44.2)  
14-27 UA/week 659 (12.8) 254 (15.9)  
≥28 UA/week 166 (3.2) 86 (5.4)  
Smoking categories (%)   0.024 
Never 2119 (41.3) 613 (38.4)  
Former 1670 (32.6) 513 (32.1)  
Current 1342 (26.2) 470 (29.5)  
Blood markers    
Fasting plasma glucose (mmol/l) 5.3 ± 0.6 6.2 ± 2 <0.001 
Triglycerides (mmol/l) 1.33 ± 1.09 1.60 ± 1.39 <0.001 § 
HDL (mmol/l) 1.66 ± 0.44 1.54 ± 0.43 <0.001 
Uric acid (µmol/l) 307 ± 83 328 ± 89 <0.001 
UA, units of alcohol. Results expressed as average ± standard deviation or as number of participants and 
(percentage). Between-group comparisons performed using student’s t-test or Kruskal-Wallis test (§) for 
continuous variables and chi-square or Fisher’s exact test (†) for categorical variables. 
  
 
